vs
维珍大西洋航空（ATLN）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是维珍大西洋航空的1.7倍（$207.3M vs $120.0M），维珍大西洋航空净利率更高（-22.6% vs -62.0%，领先39.4%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -7.3%），维珍大西洋航空自由现金流更多（$-8.2M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 9.2%）
维珍大西洋航空（简称维珍航空）是英国知名航空公司，总部位于英格兰西萨塞克斯郡克劳利。该公司成立于1984年，最初名为不列颠大西洋航空，创始人原本计划开通伦敦至福克兰群岛的航线，更名后创始人之一将股份售予理查德·布兰森，如今是英国航空市场的核心运营商之一。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
ATLN vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $120.0M | $207.3M |
| 净利润 | $-27.1M | $-128.6M |
| 毛利率 | 9.1% | — |
| 营业利润率 | -19.5% | -54.7% |
| 净利率 | -22.6% | -62.0% |
| 营收同比 | -7.3% | 25.9% |
| 净利润同比 | 60.5% | 3.5% |
| 每股收益（稀释后） | $-0.48 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $120.0M | $207.3M | ||
| Q3 25 | $110.1M | $159.9M | ||
| Q2 25 | $102.9M | $166.5M | ||
| Q1 25 | $102.8M | $139.3M | ||
| Q4 24 | $129.5M | $164.6M | ||
| Q3 24 | $107.8M | $139.5M | ||
| Q2 24 | $104.6M | $147.0M | ||
| Q1 24 | $100.6M | $108.8M |
| Q4 25 | $-27.1M | $-128.6M | ||
| Q3 25 | $-10.8M | $-180.4M | ||
| Q2 25 | $-10.7M | $-115.0M | ||
| Q1 25 | $-10.7M | $-151.1M | ||
| Q4 24 | $-68.7M | $-133.2M | ||
| Q3 24 | $-7.0M | $-133.5M | ||
| Q2 24 | $-54.9M | $-131.6M | ||
| Q1 24 | $-4.9M | $-170.7M |
| Q4 25 | 9.1% | — | ||
| Q3 25 | 11.3% | — | ||
| Q2 25 | 11.1% | — | ||
| Q1 25 | 10.9% | — | ||
| Q4 24 | 10.3% | — | ||
| Q3 24 | 11.0% | — | ||
| Q2 24 | 11.0% | — | ||
| Q1 24 | 10.4% | — |
| Q4 25 | -19.5% | -54.7% | ||
| Q3 25 | -7.9% | -106.9% | ||
| Q2 25 | -8.4% | -64.8% | ||
| Q1 25 | -9.2% | -102.6% | ||
| Q4 24 | -4.5% | -74.3% | ||
| Q3 24 | -6.0% | -94.6% | ||
| Q2 24 | -7.9% | -79.1% | ||
| Q1 24 | -1.1% | -151.9% |
| Q4 25 | -22.6% | -62.0% | ||
| Q3 25 | -9.8% | -112.8% | ||
| Q2 25 | -10.4% | -69.0% | ||
| Q1 25 | -10.5% | -108.5% | ||
| Q4 24 | -53.0% | -80.9% | ||
| Q3 24 | -6.5% | -95.7% | ||
| Q2 24 | -52.5% | -89.5% | ||
| Q1 24 | -4.8% | -156.8% |
| Q4 25 | $-0.48 | $-1.28 | ||
| Q3 25 | $-0.20 | $-1.81 | ||
| Q2 25 | $-0.20 | $-1.17 | ||
| Q1 25 | $-0.20 | $-1.57 | ||
| Q4 24 | $-1.37 | $-1.34 | ||
| Q3 24 | $-0.16 | $-1.40 | ||
| Q2 24 | $-1.96 | $-1.52 | ||
| Q1 24 | $-0.19 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $81.1K | $421.0M |
| 总债务越低越好 | $84.7M | — |
| 股东权益账面价值 | $-32.1M | $-80.0M |
| 总资产 | $113.2M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $81.1K | $421.0M | ||
| Q3 25 | $83.4K | $202.5M | ||
| Q2 25 | $374.7K | $176.3M | ||
| Q1 25 | $1.5M | $127.1M | ||
| Q4 24 | $678.7K | $174.0M | ||
| Q3 24 | $1.4M | $150.6M | ||
| Q2 24 | $439.5K | $480.7M | ||
| Q1 24 | $1.7M | $112.3M |
| Q4 25 | $84.7M | — | ||
| Q3 25 | $76.4M | — | ||
| Q2 25 | $75.4M | — | ||
| Q1 25 | $66.9M | — | ||
| Q4 24 | $80.6M | — | ||
| Q3 24 | $80.8M | — | ||
| Q2 24 | $78.5M | — | ||
| Q1 24 | — | — |
| Q4 25 | $-32.1M | $-80.0M | ||
| Q3 25 | $-22.1M | $9.2M | ||
| Q2 25 | $-18.5M | $151.3M | ||
| Q1 25 | $-14.0M | $144.2M | ||
| Q4 24 | $-12.0M | $255.0M | ||
| Q3 24 | $16.2M | $346.8M | ||
| Q2 24 | $23.0M | $432.4M | ||
| Q1 24 | $16.8M | $140.3M |
| Q4 25 | $113.2M | $1.5B | ||
| Q3 25 | $110.3M | $1.2B | ||
| Q2 25 | $106.8M | $1.3B | ||
| Q1 25 | $106.5M | $1.3B | ||
| Q4 24 | $119.8M | $1.5B | ||
| Q3 24 | $135.6M | $1.5B | ||
| Q2 24 | $134.2M | $1.6B | ||
| Q1 24 | $3.4M | $1.3B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.98× | — | ||
| Q2 24 | 3.41× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-8.2M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-8.2M | $-100.8M |
| 自由现金流率自由现金流/营收 | -6.8% | -48.6% |
| 资本支出强度资本支出/营收 | 0.0% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-4.5M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $-8.2M | $-99.8M | ||
| Q3 25 | $-1.3M | $-91.4M | ||
| Q2 25 | $-9.5M | $-108.3M | ||
| Q1 25 | $14.6M | $-166.5M | ||
| Q4 24 | $-426.3K | $-79.3M | ||
| Q3 24 | $-1.3M | $-67.0M | ||
| Q2 24 | $-15.5M | $-77.0M | ||
| Q1 24 | $11.2M | $-190.7M |
| Q4 25 | $-8.2M | $-100.8M | ||
| Q3 25 | $-1.3M | $-92.7M | ||
| Q2 25 | $-9.5M | $-110.7M | ||
| Q1 25 | $14.6M | $-167.8M | ||
| Q4 24 | $-449.4K | $-79.5M | ||
| Q3 24 | $-1.4M | $-68.6M | ||
| Q2 24 | $-15.5M | $-79.0M | ||
| Q1 24 | $11.2M | $-193.9M |
| Q4 25 | -6.8% | -48.6% | ||
| Q3 25 | -1.2% | -58.0% | ||
| Q2 25 | -9.3% | -66.5% | ||
| Q1 25 | 14.2% | -120.5% | ||
| Q4 24 | -0.3% | -48.3% | ||
| Q3 24 | -1.3% | -49.2% | ||
| Q2 24 | -14.8% | -53.7% | ||
| Q1 24 | 11.2% | -178.2% |
| Q4 25 | 0.0% | 0.5% | ||
| Q3 25 | 0.0% | 0.8% | ||
| Q2 25 | 0.0% | 1.5% | ||
| Q1 25 | 0.0% | 1.0% | ||
| Q4 24 | 0.0% | 0.1% | ||
| Q3 24 | 0.0% | 1.2% | ||
| Q2 24 | 0.0% | 1.4% | ||
| Q1 24 | 0.0% | 3.0% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATLN
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
